Lead new indication strategy and planning across oncology indications, working cross-functionally to guide late-stage clinical development strategy.
Deliver strategic market and competitive intelligence insights through research, scenario planning, and impact assessments to guide executive decision-making.
Develop NPV, forecasting, and revenue modeling for new indications up to 18 months before launch, providing data-driven assumptions for early commercial planning.
Own the commercial assessment of pipeline assets, including market sizing, target product profiles, and competitive analysis.
Drive portfolio prioritization, forecasting, and commercial recommendations to inform Go/No-Go decisions for registrational trials.
Represent Commercial in enterprise forums, operating as the strategic integrator to align stakeholders and drive execution.
Iovance Biotherapeutics is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. The company operates as an end-to-end cell therapy organization with fully owned, centralized U.S.-based manufacturing, serving thousands of cancer patients worldwide each year.
Drive commercial growth by developing multi-year business plans and leading key oncology accounts.
Educate healthcare leaders on cell therapy logistics and resolve access barriers with cross-functional teams.
Serve as a field leader, coaching colleagues and ensuring compliance with all policies and regulations.
Iovance Biotherapeutics is a biotechnology company that develops and delivers tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. As the first company to commercialize TIL therapy, it operates a large-scale U.S. manufacturing facility and promotes a collaborative, patient-focused culture.
Lead corporate demand forecasting for neffy, including scenario analysis and variance tracking.
Drive commercial assessments for lifecycle opportunities and pipeline assets, supporting strategic decisions.
Oversee market insights and competitive intelligence functions, aligning research with leadership needs.
ARS Pharmaceuticals is a fast-growing, innovative company dedicated to transforming the treatment of severe allergic reactions with neffy, the first and only FDA-approved needle-free epinephrine product. The company fosters a collaborative, entrepreneurial, and inclusive culture, operating as a focused biotechnology organization.